ReviewNeuroradiology2025
Efficacy and safety of p48 flow diverters in the treatment of intracranial aneurysms: A systematic review and Meta-Analysis.
Review in Neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe p48 movable wire (MW) flow modulation devices are a group of novel low-profile flow diverters (FDs) that have recently been introduced for the management of small intracranial aneurysms (IAs). This study evaluates the current literature regarding the efficacy and safety of p48 in treating IAs.
methodsA literature search was conducted using the PubMed, Embase, Scopus, and Web of Science databases. Studies evaluating the role of p48 FDs in IAs were included.
resultsTwelve studies encompassing 312 individuals with 330 IAs were included. The meta-analysis revealed a pooled complete occlusion rate of 58% (95% CI: 40%-75%), a favorable outcome rate of 96% (95% CI: 86%-100%), and a morbidity rate of 1% (95% CI: 0%-3%). Regarding the complications, our findings showed a pooled intraprocedural rate of 7% (95% CI: 1%-16%), a postprocedural rate of 9% (95% CI: 6%-13%), an ischemic complication rate of 8% (95% CI: 5%-12%), a hemorrhagic complication rate of 3% (95% CI: 1%-5%), and an in-stent stenosis rate of 1% (95% CI: 0%-3%). The subgroup analysis comparing p48 MW and p48 MW with a hydrophilic coating (HPC) did not demonstrate significant differences between groups in outcomes and complications, except for hemorrhagic complications, which were higher in p48 MW than in p48 MW HPC devices (p48: 3% vs. p48 HPC: 0%, P = 0.04).
conclusionThe p48 FDs represent novel therapeutic options in the management of IAs, associated with promising outcomes and low complication rates.
Indexed as
Identifiers
40788393What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.